Jaguar Health, Inc. (JAGX)
NASDAQ (CM) NASDAQ (CM) Primary 
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day's action on the companies themselves rather than on any broader rotation.
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn't selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript
Jaguar Health, Inc. ( JAGX ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Lisa Conte - Founder, CEO, President & Director Carol Lizak - Chief Financial Officer Presentation Operator Greetings, and welcome to the Jaguar Health's Investor Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ:JAGX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Carol R. Lizak - Chief Financial Officer Lisa A.
Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2025 Earnings Conference Call May 15, 2025 4:15 PM ET Company Participants Lisa Conte – Founder, President, and Chief Executive Officer Carol Lizak – Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to Jaguar Health's May 15, 2025 Investor Webcast. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript
Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Investor Webcast. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat on January 13, 2025 at the Lytham Partners 2025 Investor Healthcare Summit and in person on January 14, 2025 at Biotech Showcase. Participation Instructions for Jaguar Health's Virtual Fireside Chat at the Lytham Partners 2025 Investor Healthcare Summit When: Monday, January 13, 2025 at 12:00 PM Eastern Standard TimeWhere: Online (Click Here).
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both MVID and SBS-IF SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of MVID in pediatric patients, has been initiated. "The initiation of this double blind, placebo-controlled study in pediatric MVID patients is a key milestone for Jaguar," said Lisa Conte, Jaguar's founder, president, and CEO.
